PCC Rokita SA (PCR)
Warsaw Stock Exchange · Poland · prices in PLN · close of 22 Oct 2026
Key indicators
| Last close | PLN 62.90 |
|---|---|
| 52-week range | 58.40 – 74.40 |
| Return, 1 month / 3 months | −6.3% / −9.8% |
| Return, 1 year / 3 years | −3.7% / −15.3% |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 23.8% |
| Worst drawdown (1 year) | -15.4% |
| Average daily value traded | 0.48M PLN |
| Dividend yield | 4.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
PCC Rokita is a chemical company based in Brzeg Dolny, Poland. It makes chlorine, caustic soda and other inorganic chemicals, together with polyols and specialty chemical products. Its customers are industrial firms that use these materials in manufacturing, construction, furniture and other sectors. The company operates production plants and sells its chemicals to customers in Poland and abroad, serving both large industrial buyers and smaller specialised users of its product range.
On this site PCC Rokita SA appears as a stock on the Warsaw Stock Exchange (Poland), code PCR, with prices in Polish zloty (PLN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
PCC Rokita SA (PCR) trades on the Warsaw Stock Exchange in Poland. It last closed at PLN 62.90 on 22 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 153 of 580 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 3.7% and over the last three months it fell 9.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Warsaw Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 52 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -5.8% | ||
| From 52-week high | -15.2% | ||
| Momentum | 44 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -9.8% | ||
| 6-month return | -3.4% | ||
| 12-month return, skipping the last month | 2.8% | ||
| Stability (higher is calmer) | 91 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -15.4% | ||
| Liquidity | 81 · Strong | Trades actively. | |
| Average daily value traded | 0.48M PLN | ||
| Zero-volume days | 0.0% | ||
| Income | 58 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.2% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −2.5% |
|---|---|
| 1 month | −6.3% |
| 3 months | −9.8% |
| 6 months | −3.4% |
| 1 year | −3.7% |
| 3 years | −15.3% |
| 5 years | +5.7% |
Signals
| 50-day / 200-day average | 65.76 / 66.79 |
|---|---|
| Golden / death cross (60 days) | Death, 14 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.25 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Apr 2026 | PLN 2.6500 |
| 2 May 2025 | PLN 5.0500 |
| 23 May 2024 | PLN 6.7000 |
| 4 May 2023 | PLN 21.5700 |
| 26 Apr 2022 | PLN 13.2300 |
| 5 May 2021 | PLN 3.6700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Warsaw Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.